Work

(093) Impact of Enrollment Diagnosis on Efficacy Endpoints in an Exploratory, Phase 2b, Randomized, Double-blind, Placebo-controlled Clinical Trial of Sildenafil Cream, 3.6% for the Treatment of Female Sexual Arousal Disorder

Year: 2024

Type: article

Source: The Journal of Sexual Medicine

DOI: 10.1093/jsxmed/qdae054.088

Authors: A Thurman, K Cornell, T Symonds, C Dart, J Hatheway, D Friend, A Goldstein

Institutions: Daré Bioscience, Inc. (United States), Strategic Science & Technologies (United States), Premier Research Group

Language: English

Topic: Sexual function and dysfunction studies

Subfield: Psychiatry and Mental health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4399760627

FWCI:

Cites:

Cited by:

Related to: 10